52In the second place, it should be noted that it is in a context of balance between two complementary objectives, namely, first, to promote research on new therapeutic indications with a significant clinical benefit and bringing an improvement to the quality of life and welfare of the patient and, second, to favour the production of generic medicinal products, that the EU legislature provided that the additional year of marketing protection, provided for in Article 14(11) of Regulation No 726/2004, may be granted only where the new therapeutic indication is authorised within the first 8 years of those 10 years. That additional year of market exclusivity therefore constitutes, in the view of the EU legislature, the appropriate advantage to reward the investments in new therapeutic indications (judgment of 28 June 2017, Novartis Europharm v Commission, C‑629/15 P and C‑630/15 P, EU:C:2017:498, paragraphs 77 and 78).